Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by acute eczema or chronic lichenified lesions with heterogeneity. This skin disease affects almost 10-20% of people worldwide. The course involves chronic relapses that significantly reduce the patient's quality of life. Biomarkers have always existed for various purposes in medicine, especially as a diagnostic tool. However, there is currently a shortage of suitable biomarkers for atopic dermatitis, largely due to difficulties in sampling. Purpose: To find out the latest biomarkers that can be used in patients with atopic dermatitis. Method: Literature review are taken from PubMed and Google Scholar databases published within the last 5 years, from 2018-2022. Results: Based on the literature, there are several biomarkers that can be used for patients with atopic dermatitis including TARC or CCL17, CCL27, phytosphingosine CD300a, Interleukin-1 family (IL-18, IL1?, CXCL8), adipokines, FABP5, filaggrin. Conclusion: From the literature it was found that there are several current biomarkers for patients with atopic dermatitis that can be used as markers of clinical disease severity and monitoring of disease progression, as prognostic markers, screening and diagnosis tools.